User profiles for "author:Theerada Assawasaksakul"
 | Theerada AssawasaksakulRheumatologist, Chulalongkorn University, King Chulalongkorn Memorial Hospital Verified email at chula.ac.th Cited by 96 |
[HTML][HTML] A comparative study of conventional cytology and cell block method in the diagnosis of pleural effusion
T Assawasaksakul, V Boonsarngsuk… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
Background In a patient with pleural effusion, cytological study (CS) is one of the most useful
investigations, especially when malignancy is suspected. Instead of applying only CS, the …
investigations, especially when malignancy is suspected. Instead of applying only CS, the …
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid …
T Assawasaksakul, S Sathitratanacheewin… - Lupus Science & …, 2022 - lupus.bmj.com
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2
boosters in patients with SLE and rheumatoid arthritis (RA). Methods Patients with SLE and …
boosters in patients with SLE and rheumatoid arthritis (RA). Methods Patients with SLE and …
[HTML][HTML] Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored/mRNA vaccines in patients with …
T Assawasaksakul, T Lertussavavivat… - Vaccines, 2022 - mdpi.com
Background: Impaired immune responses to COVID-19 vaccines have been observed in
autoimmune rheumatic disease patients. Determining the most effective and safe vaccine …
autoimmune rheumatic disease patients. Determining the most effective and safe vaccine …
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: A case series
T Assawasaksakul, S Sathitratanacheewin… - RMD open, 2021 - rmdopen.bmj.com
Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been
widely deployed in several countries for emergency use. However, the immunogenicity of …
widely deployed in several countries for emergency use. However, the immunogenicity of …
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and …
T Assawasaksakul, S Sathitratanacheewin… - medRxiv, 2022 - medrxiv.org
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2
boosters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients …
boosters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients …
Urine γ-interferon-inducible protein (IP-10) as a biomarker of histological activity of lupus nephritis
K Prasopsanti, T Supasiri, Y Avihingsanon… - medRxiv, 2022 - medrxiv.org
Introduction Conventional markers are not reliable predictors of histological activity of lupus
nephritis (LN). We aimed to examine the utility of urine γ-interferon-inducible protein (IP-10) …
nephritis (LN). We aimed to examine the utility of urine γ-interferon-inducible protein (IP-10) …
[HTML][HTML] Clinical case: Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients …
T Assawasaksakul, S Sathitratanacheewin… - RMD …, 2021 - ncbi.nlm.nih.gov
Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been
widely deployed in several countries for emergency use. However, the immunogenicity of …
widely deployed in several countries for emergency use. However, the immunogenicity of …